Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-13 (Cancelled)

Claim 14 (Currently amended): A method of inhibiting complement activity comprising administering an effective amount of protein to a mammal human, rat, or mouse subject, the protein having an comprising the amino acid sequence that is at least 95 percent homologous to a protein selected from the group consisting of proteins having the sequence of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 19, and SEQ ID NO: 23.

Claim 15 (Previously Presented): The method of claim 14, wherein the mammal is a human.

Claims 16-19 (Cancelled)

Claim 20 (Previously Presented): The method of claim 14, the protein being selected from the group consisting of proteins having the sequence of SEQ ID NO: 13 and SEQ ID NO: 15.